Journal of pharmacy & bioallied sciences · 2025
Comparative Effect of SGLT2 Inhibitors and GLP-1 Agonists on Glycemic Control in Type 2 Diabetes Mellitus.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Prakash Ved, Gupta Sangeeta, Singh Saumya, Rawat Anurag, Deshpande Amit Vasant, Podder Amrit, Jani Parth
Аннотация
INTRODUCTION: The goal of this study was to find out how SGLT2 inhibitors and GLP-1 receptor agonists help persons with Type 2 Diabetes Mellitus (T2DM) keep their blood sugar levels stable.
METHODOLOGY: There were 120 people in the trial. They were randomly given either empagliflozin, Canagliflozin, Dapagliflozin, Ertugliflozin, Bexagliflozin, Sotagliflozin (an SGLT2 inhibitor) or liraglutide, Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin (n GLP-1 receptor agonist) to consume for 24 weeks. The major goal was to lower the levels of HbA1c. Some of the secondary outcomes included losing weight, markers of heart health, and adverse events.
RESULTS: Both treatments brought down HbA1c levels a lot, although GLP-1 agonists brought them down a little bit more. Both groups' systolic blood pressure and LDL cholesterol levels improved, but the group that took GLP-1 agonists lost more weight. People who took SGLT2 inhibitors didn't have as many stomach problems, whereas people who took GLP-1 agonists got nauseated and threw up.
CONCLUSION: The study showed that both types of medicines do a decent job of keeping blood sugar levels steady. But GLP-1 agonists are better at helping people lose weight and keep their hearts healthy, so they are also a fantastic choice for people who have these problems. It's crucial to consider what each patient needs and what could go wrong while establishing treatment plans for them.
METHODOLOGY: There were 120 people in the trial. They were randomly given either empagliflozin, Canagliflozin, Dapagliflozin, Ertugliflozin, Bexagliflozin, Sotagliflozin (an SGLT2 inhibitor) or liraglutide, Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin (n GLP-1 receptor agonist) to consume for 24 weeks. The major goal was to lower the levels of HbA1c. Some of the secondary outcomes included losing weight, markers of heart health, and adverse events.
RESULTS: Both treatments brought down HbA1c levels a lot, although GLP-1 agonists brought them down a little bit more. Both groups' systolic blood pressure and LDL cholesterol levels improved, but the group that took GLP-1 agonists lost more weight. People who took SGLT2 inhibitors didn't have as many stomach problems, whereas people who took GLP-1 agonists got nauseated and threw up.
CONCLUSION: The study showed that both types of medicines do a decent job of keeping blood sugar levels steady. But GLP-1 agonists are better at helping people lose weight and keep their hearts healthy, so they are also a fantastic choice for people who have these problems. It's crucial to consider what each patient needs and what could go wrong while establishing treatment plans for them.